Suppression of Experimental Allergic Encephalomyelitis by NSC 82196, a New Imidazole Carboxamide Derivative

Charles L. Vogel; Vincent T. De Vita; Robert P. Lisak; Marian W. Kies

Suppression of Experimental Allergic Encephalomyelitis by NSC 82196, a New Imidazole Carboxamide Derivative

Charles L. Vogel, Vincent T. De Vita, Robert P. Lisak, Marian W. Kies

Research output: Contribution to journal › Article › peer-review

Abstract

Experimental allergic encephalomyelitis (EAE) was used as a model delayed hypersensitivity reaction to test the immunosuppressive potential of the new carcinostatic agent, imidazole-4(or 5)-carboxamide,5(or 4)-[3,3-bis-(2-chloroethyl)-l-triazeno] (NSC 82196). EAE was induced in the highly susceptible Lewis strain of rats by intradermal injection of an encephalitogenic protein extracted from guinea pig brain emulsified in Freund's complete adjuvant. NSC 82196 delayed the onset and significantly decreased the severity of EAE when given prior to antigenic challenge. This drug was more effective in suppressing EAE than equitoxic doses of a related compound, NSC 45388, and the other immunosuppressive agents tested, cyclophosphamide, nitrogen mustard, azathioprine, and amethopterin, when all drugs were given in a similar presensitization schedule. EAE can be used as an effective screening model for immunosuppressive effects of drugs that may have pertinence in cancer chemotherapy.

Original language	English (US)
Pages (from-to)	2249-2253
Number of pages	5
Journal	Cancer Research
Volume	29
Issue number	12
State	Published - Dec 1969
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Fingerprint Dive into the research topics of 'Suppression of Experimental Allergic Encephalomyelitis by NSC 82196, a New Imidazole Carboxamide Derivative'. Together they form a unique fingerprint.

Cite this

@article{077b8abfa9904e08a35767605f733b54,

title = "Suppression of Experimental Allergic Encephalomyelitis by NSC 82196, a New Imidazole Carboxamide Derivative",

abstract = "Experimental allergic encephalomyelitis (EAE) was used as a model delayed hypersensitivity reaction to test the immunosuppressive potential of the new carcinostatic agent, imidazole-4(or 5)-carboxamide,5(or 4)-[3,3-bis-(2-chloroethyl)-l-triazeno] (NSC 82196). EAE was induced in the highly susceptible Lewis strain of rats by intradermal injection of an encephalitogenic protein extracted from guinea pig brain emulsified in Freund's complete adjuvant. NSC 82196 delayed the onset and significantly decreased the severity of EAE when given prior to antigenic challenge. This drug was more effective in suppressing EAE than equitoxic doses of a related compound, NSC 45388, and the other immunosuppressive agents tested, cyclophosphamide, nitrogen mustard, azathioprine, and amethopterin, when all drugs were given in a similar presensitization schedule. EAE can be used as an effective screening model for immunosuppressive effects of drugs that may have pertinence in cancer chemotherapy.",

author = "Vogel, {Charles L.} and {De Vita}, {Vincent T.} and Lisak, {Robert P.} and Kies, {Marian W.}",

year = "1969",

month = dec,

language = "English (US)",

volume = "29",

pages = "2249--2253",

journal = "Cancer Research",

issn = "0008-5472",

number = "12",

}

TY - JOUR

T1 - Suppression of Experimental Allergic Encephalomyelitis by NSC 82196, a New Imidazole Carboxamide Derivative

AU - Vogel, Charles L.

AU - De Vita, Vincent T.

AU - Lisak, Robert P.

AU - Kies, Marian W.

PY - 1969/12

Y1 - 1969/12

N2 - Experimental allergic encephalomyelitis (EAE) was used as a model delayed hypersensitivity reaction to test the immunosuppressive potential of the new carcinostatic agent, imidazole-4(or 5)-carboxamide,5(or 4)-[3,3-bis-(2-chloroethyl)-l-triazeno] (NSC 82196). EAE was induced in the highly susceptible Lewis strain of rats by intradermal injection of an encephalitogenic protein extracted from guinea pig brain emulsified in Freund's complete adjuvant. NSC 82196 delayed the onset and significantly decreased the severity of EAE when given prior to antigenic challenge. This drug was more effective in suppressing EAE than equitoxic doses of a related compound, NSC 45388, and the other immunosuppressive agents tested, cyclophosphamide, nitrogen mustard, azathioprine, and amethopterin, when all drugs were given in a similar presensitization schedule. EAE can be used as an effective screening model for immunosuppressive effects of drugs that may have pertinence in cancer chemotherapy.

AB - Experimental allergic encephalomyelitis (EAE) was used as a model delayed hypersensitivity reaction to test the immunosuppressive potential of the new carcinostatic agent, imidazole-4(or 5)-carboxamide,5(or 4)-[3,3-bis-(2-chloroethyl)-l-triazeno] (NSC 82196). EAE was induced in the highly susceptible Lewis strain of rats by intradermal injection of an encephalitogenic protein extracted from guinea pig brain emulsified in Freund's complete adjuvant. NSC 82196 delayed the onset and significantly decreased the severity of EAE when given prior to antigenic challenge. This drug was more effective in suppressing EAE than equitoxic doses of a related compound, NSC 45388, and the other immunosuppressive agents tested, cyclophosphamide, nitrogen mustard, azathioprine, and amethopterin, when all drugs were given in a similar presensitization schedule. EAE can be used as an effective screening model for immunosuppressive effects of drugs that may have pertinence in cancer chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0014634197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0014634197&partnerID=8YFLogxK

M3 - Article

C2 - 5369677

AN - SCOPUS:0014634197

VL - 29

SP - 2249

EP - 2253

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 12

ER -

Suppression of Experimental Allergic Encephalomyelitis by NSC 82196, a New Imidazole Carboxamide Derivative

Abstract

ASJC Scopus subject areas

Other files and links

Cite this